BioCentury
ARTICLE | Company News

Cell Therapeutics receives Trisenox approval

September 26, 2000 7:00 AM UTC

The FDA granted marketing approval to CTIC for its Trisenox arsenic trioxide injection to treat relapsed or refractory acute promyelocytic leukemia (APL). The company submitted the NDA in April. Trise...